Mouse RAGE/AGER Antibody Summary
Gly23-Leu342
Accession # NP_031451
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
Detection of Mouse and Rat RAGE by Western Blot. Western blot shows lysates of mouse lung tissue, Neuro-2A mouse neuroblastoma cell line, and rat lung tissue. PVDF membrane was probed with 1 µg/mL of Rat Anti-Mouse RAGE Monoclonal Antibody (Catalog # MAB11795) followed by HRP-conjugated Anti-Rat IgG Secondary Antibody (HAF005). Specific bands were detected for RAGE at approximately 45 to 50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
Detection of RAGE in Mouse Splenocytes by Flow Cytometry. Mouse splenocytes stimulated to induce Th1 cells were stained with Rat Anti-Mouse CD4 PE-conjugated Monoclonal Antibody (FAB554P) and either (A) Rat Anti-Mouse RAGE Monoclonal Antibody (Catalog # MAB11795) or (B) Rat IgG2AIsotype Control (MAB006) followed by Allophycocyanin-conjugated Anti-Rat IgG Secondary Antibody (F0113). View our protocol for Staining Membrane-associated Proteins.
Detection of Mouse AGER by Immunocytochemistry/Immunofluorescence Treatment with anti-M7 prevents inflammatory leukocyte recruitment in vitro and in vivo. a Murine peritoneal macrophages were incubated on dishes coated with mouse CD40L in the presence of 10μg/ml of IgG, anti-M7, or anti-Mac-1 (clone M1/70). Adhering cells were normalized to % of the IgG-treatment. b Murine RAW-cell adhesion on TNF alpha -primed murine endothelial cells under physiological flow in the presence of IgG or anti-M7 antibodies (10 μg/ml). c–f C57Bl/6 mice were injected i.p. with 200 ng TNF alpha and 15 min before microscopy with Fab fragments of an IgG control antibody, or antibodies against RAGE, ICAM-1, LFA-1, Mac-1 (clone M1/70), or anti-M7 (100 μg i.p.). Leukocyte recruitment was monitored by intravital microscopy 4 h later: Adhering (d) and rolling leukocytes (e) were quantified as % of IgG. (f) Cumulative frequency of leukocyte rolling velocity. g Leukocyte adhesion in intravital microscopy in IgG or anti-M7 treated WT and Mac-1−/− mice. h, i Number of CX3CR1-GFP+ monocytes (white arrows) in the para-vascular space 4 h after treatment with IgG or anti-M7 and 200ng TNF alpha. j Confocal in vivo imaging of the greater omentum after local stimulation with TNF alpha and i.v. injection of the indicated antibodies (100 μg) in LysM-GFP reporter mice. LysM-GFP+ myeloid cells were tracked over time. Time lapse and cell tracking is shown over 15 min (right panel). k Plasma cytokine levels of mice subjected to intravital microscopy after IgG or anti-M7 Fab treatment. l Peritoneal exudate cells (PECs) 72 h after induction of a sterile peritonitis and the indicated antibody treatment. Scale bars represent 100μm (c, h, j). Error bars indicate mean ± SEM. Statistical significance was assessed by a two-sided, unpaired Student’s T-test between the indicated groups (a, b, g, i, k, l) or in comparison to IgG-treatment (d, e). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. N ≥ 3 independent experiments (a, b). N ≥ 10 mice per group (d, e, f, g), N ≥ 6 mice per group (l, h) Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29410422), licensed under a CC-BY license. Not internally tested by R&D Systems.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: RAGE/AGER
Advanced glycation endproducts (AGE) are adducts formed by the non-enzymatic glycation or oxidation of macromolecules (1). AGE forms during aging and its formation is accelerated under pathophysiologic states such as diabetes, Alzheimer’s disease, renal failure and immune/inflammatory disorders. Receptor for Advanced Glycation Endoproducts (RAGE), named for its ability to bind AGE, is a multiligand receptor belonging the immunoglobulin (Ig) superfamily. Besides AGE, RAGE binds amyloid beta -peptide, S100/calgranulin family proteins, high mobility group B1 (HMGB1, also know as amphoterin) and leukocyte integrins (1, 2).
The mouse RAGE gene encodes a 403 amino acid (aa) residue type I transmembrane glycoprotein with a 22 aa signal peptide, a 319 aa extracellular domain containing a Ig-like V-type domain and two Ig-like Ce-type domains, a 21 aa transmembrane domain and a 41 aa cytoplasmic domain (3). The V-type domain and the cytoplasmic domain are important for ligand binding and for intracellular signaling, respectively. Two alternative splice variants, lacking the V-type domain or the cytoplasmic tail, are known (1, 4). RAGE is highly expressed in the embryonic central nervous system (5). In adult tissues, RAGE is expressed at low levels in multiple tissues including endothelial and smooth muscle cells, mononuclear phagocytes, pericytes, microglia, neurons, cardiac myocytes and hepatocytes (6). The expression of RAGE is upregulated upon ligand interaction. Depending on the cellular context and interacting ligand, RAGE activation can trigger differential signaling pathways that affect divergent pathways of gene expression (1, 7). RAGE activation modulates varied essential cellular responses (including inflammation, immunity, proliferation, cellular adhesion and migration) that contribute to cellular dysfunction associated with chronic diseases such as diabetes, cancer, amyloidoses and immune or inflammatory disorders (1).
- Schmidt, A. et al. (2001) J. Clin. Invest. 108:949.
- Chavakis, T. et al. (2003) J. Exp. Med. 198:507.
- Renard, C. et al. (1997) Mol. Pharmacol. 52:54.
- Yonekura, H. et al. (2003) Biochem. J. 370:1097.
- Hori, O. et al. (1995) J. Biol. Chem. 270:25752.
- Brett, J. et al. (1993) Am. J. Pathol. 143:1699.
- Valencia, J.V. et al. (2004) Diabetes 53:743.
Product Datasheets
Citations for Mouse RAGE/AGER Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
3
Citations: Showing 1 - 3
Filter your results:
Filter by:
-
Serum developmental endothelial locus-1 is associated with severity of sepsis in animals and humans
Authors: WY Kim, SH Lee, DY Kim, HJ Ryu, GR Chon, YY Park, Y Fu, JW Huh, CM Lim, Y Koh, EY Choi, SB Hong
Sci Rep, 2019-09-10;9(1):13005.
Species: Mouse
Sample Types: Serum
Applications: ELISA Capture -
Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer’s disease
Authors: Philippe Bourassa, Cyntia Tremblay, Julie A. Schneider, David A. Bennett, Frédéric Calon
Acta Neuropathologica
-
TFAM is a novel mediator of immunogenic cancer cell death
Authors: Minghua Yang, Changfeng Li, Shan Zhu, Lizhi Cao, Guido Kroemer, Herbert Zeh et al.
OncoImmunology
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Mouse RAGE/AGER Antibody
There are currently no reviews for this product. Be the first to review Mouse RAGE/AGER Antibody and earn rewards!
Have you used Mouse RAGE/AGER Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image